TISIDB

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm, cell cortex Cytoplasm, perinuclear region Cytoplasm, cytoskeleton Note=In undifferentiated cells colocalizes with F-actin in the cell periphery while in differentiated cells its localization is cytoplasmic with the highest levels in the perinuclear region.
Domain	PF00612 IQ calmodulin-binding motif PF00063 Myosin head (motor domain) PF00788 Ras association (RalGDS/AF-6) domain PF00620 RhoGAP domain
Function	Myosins are actin-based motor molecules with ATPase activity. Unconventional myosins serve in intracellular movements. Binds actin with high affinity both in the absence and presence of ATP and its mechanochemical activity is inhibited by calcium ions (PubMed:9490638). Also acts as a GTPase activator for RHOA (PubMed:9490638, PubMed:26529257). Plays a role in the regulation of cell migration via its role as RHOA GTPase activator. This is regulated by its interaction with the SLIT2 receptor ROBO1; interaction with ROBO1 impairs interaction with RHOA and subsequent activation of RHOA GTPase activity, and thereby leads to increased levels of active, GTP-bound RHOA (PubMed:26529257).

> Gene Ontology [ TOP ]
Biological Process	GO:0007265 Ras protein signal transduction GO:0007266 Rho protein signal transduction GO:0030048 actin filament-based movement GO:0035023 regulation of Rho protein signal transduction GO:0035385 Roundabout signaling pathway GO:0046578 regulation of Ras protein signal transduction GO:0051056 regulation of small GTPase mediated signal transduction
Molecular Function	GO:0000146 microfilament motor activity GO:0003774 motor activity GO:0003779 actin binding GO:0005096 GTPase activator activity GO:0005516 calmodulin binding GO:0008047 enzyme activator activity GO:0016887 ATPase activity GO:0017016 Ras GTPase binding GO:0017048 Rho GTPase binding GO:0030695 GTPase regulator activity GO:0031267 small GTPase binding GO:0043531 ADP binding GO:0048495 Roundabout binding GO:0051020 GTPase binding GO:0060589 nucleoside-triphosphatase regulator activity
Cellular Component	GO:0005884 actin filament GO:0005938 cell cortex GO:0015629 actin cytoskeleton GO:0016459 myosin complex GO:0099568 cytoplasmic region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-2029480: Fcgamma receptor (FCGR) dependent phagocytosis R-HSA-168256: Immune System R-HSA-168249: Innate Immune System R-HSA-2029482: Regulation of actin dynamics for phagocytic cup formation R-HSA-194840: Rho GTPase cycle R-HSA-162582: Signal Transduction R-HSA-194315: Signaling by Rho GTPases

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between MYO9B and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of MYO9B in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of MYO9B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.33	0.229
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.366	0.861
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.314	0.854
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.151	0.623
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.086	0.976
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.453	0.904
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.141	0.731
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.248	0.899
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.003	0.999
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.763	0.657
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.062	0.677
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.02	0.728

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of MYO9B in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	14.3	17.6	-3.3	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	100	-90	0.014
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	25	0	25	0.222
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	1.4	6	0.177
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	1.7	5.7	0.231
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	11.8	-7	0.577
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	18.2	-10.5	0.576
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	33.3	0	33.3	0.0365
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	40	0	40	0.11
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	10.5	3.7	6.8	0.393
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	13.6	7.7	5.9	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of MYO9B. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of MYO9B. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by MYO9B. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of MYO9B. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of MYO9B expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between MYO9B and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	MYO9B
Name	myosin IXB
Aliases	CELIAC4; MYR5; myosin-IXb; unconventional myosin IXb; unconventional myosin-9b; Unconventional myosin-IXb
Chromosomal Location	19p13.11
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting MYO9B collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse MYO9B